Successful pancreatectomy after conversion-intended chemotherapy using gemcitabine and nab-paclitaxel for unresectable adenosquamous carcinoma of the pancreas: a case report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Successful pancreatectomy after conversion-intended chemotherapy using gemcitabine and nab-paclitaxel for unresectable adenosquamous carcinoma of the pancreas: a case report ; volume:10 ; number:1 ; day:16 ; month:8 ; year:2024 ; pages:1-9 ; date:12.2024
Surgical case reports ; 10, Heft 1 (16.8.2024), 1-9, 12.2024
- Urheber
-
Nakamura, Kenichi
Nakagawa, Mitsuru
Ariga, Mizuki
Higashiguchi, Takahiko
Chikaishi, Yuko
Matsuo, Kazuhiro
Nishijima, Aki
Endo, Tomoyoshi
Kikuchi, Kenji
Morohara, Koji
Katsuno, Hidetoshi
Tachi, Yoshihiko
Uyama, Ichiro
Suda, Koichi
Morise, Zenichi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40792-024-01989-5
- URN
-
urn:nbn:de:101:1-2411032133504.790982008387
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nakamura, Kenichi
- Nakagawa, Mitsuru
- Ariga, Mizuki
- Higashiguchi, Takahiko
- Chikaishi, Yuko
- Matsuo, Kazuhiro
- Nishijima, Aki
- Endo, Tomoyoshi
- Kikuchi, Kenji
- Morohara, Koji
- Katsuno, Hidetoshi
- Tachi, Yoshihiko
- Uyama, Ichiro
- Suda, Koichi
- Morise, Zenichi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Pankreaskarzinom nab-Paclitaxel
Breast cancer nab-Paclitaxel
Intensified neoadjuvant chemotherapy with nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in a patient with locally advanced unresectable pancreatic cancer
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study
Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)
Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Pankreaskarzinom nab-Paclitaxel
Breast cancer nab-Paclitaxel
Intensified neoadjuvant chemotherapy with nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in a patient with locally advanced unresectable pancreatic cancer
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study
Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)
Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Pankreaskarzinom nab-Paclitaxel
Breast cancer nab-Paclitaxel
Intensified neoadjuvant chemotherapy with nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in a patient with locally advanced unresectable pancreatic cancer
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study
Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)